Stephen Hawking had good reason to call med tech startup Medcura – “a top innovative product of this decade.” The Propel(x) alumnus company is poised to deploy a revolutionary med gel technology to rapidly stop bleeding in diverse emergency, trauma, surgical, and even everyday situations.
Hawking explains, “One of the most abundant creatures in the ocean has hidden properties that could save millions of lives each year.” The key ingredient in Medura’s gel solution is chitosan, a natural binding agent found in the exoskeleton of most shellfish. Med tech startup Medcura has developed a platform including bandages, gels, powders, and sprays that can effectively seal almost any type of bleeding.
Why though is Medcura so revolutionary that even Stephen Hawking, the renowned astrophysicist and philosopher (holder of Newton’s old chair at Cambridge University), is impressed?
How we stop bleeding hasn’t changed much in 100 years. First responders, emergency room workers, and surgeons compress the wound and wait. This approach has two major limitations; first, it’s slow, and second, it’s distracting. A first responder should focus on getting a patient to a healthcare setting. A surgeon should concentrate on the actual surgery, instead of being forced to concentrate on unwanted bleeding.
However, even the most impressive breakthroughs, especially ones founded in deep technology spaces, face financing hurdles. Capital to continue the development of its solution was critical if Medcura Life Sciences was going to commercialize its platform. Despite the heightened interest in world-changing technology, an information gap can separate investors from this type of promising opportunity.
Propel(x)’s mission is to bridge that gap and help groundbreaking innovations like Medcura Life Sciences thrive. Propel(x) aims to help these next-generation technologies quickly and efficiently.
Matthew Dowling, Medcura’s co-founder, and CSO, heard of Propel(x) from a doctor he met at a conference in San Francisco and says a big draw was the quick timing to a close. The platform exposed Medcura to a larger sophisticated investor community and supported investors’ understanding of the business.
This quick access to information supported a large investment that can help save lives through this groundbreaking innovation. Medcura is revolutionizing how we will treat bleeding. It’s effective of course, but it also is flexible for use as a nosebleed spray or gel as well as a surgical powder or foam.
Anyone, from the ER to the OR and even a Mom, can spray Medecura where necessary to quickly stop bleeding. If it can work in more dire emergencies, whether car, battlefield or even kitchen accidents, rapidly stop the traumatic bleed, precious time can be saved in getting the patient the next level of professional care.
In a hospital setting after interventional cardiology, it can decrease the time to discharge, with current postoperative hemostasis routinely taking 3+hrs. The result of Medcura: faster, better, less expensive healthcare.
The idea for Medcura began with doctors at the University of Maryland Medical School in Baltimore, where Dowling met John Hess, a former army doctor. Hess was one of the original developers of fibrin-infused dressings at the behest of the US military.
Fibrin is an insoluble protein formed during blood clot formation that becomes a fibrous mesh impedes the flow of blood and accelerates clot formation. Dowling explains, “Providing more fibrin at the site of a bleed was an excellent first-generation solution, but like all protein products, fibrin has some key drawbacks.”
Fibrin sealants can require cold storage, are generally extracted from human blood, and require complex biological manufacture. Those challenges aside, fibrin sealants are simply too expensive for use outside the hospital and certain applications for first responders. The impact of Medcura technology may be vast, as Hawking anticipates.
Medcura raised over $3.1M in 2018 and was supported by the Propel(x) investor network.
The proceeds from this round will support additional FDA submissions, new clinical trials, and larger-scale deployment of this potentially life-saving innovation across the US. They recently announced an expansion of their core team, adding a Head of Regulatory, Head of Manufacturing, and CFO to prepare for the commercialization and growth of their product line. Learn more about this med tech startup Medcura by visiting: https://www.medcurainc.com/
. . .
Articles or information from third-party sources outside of this domain may discuss Propel(x) or relate to information contained herein, but Propel(x) does not approve and is not responsible for such content. Hyperlinks to third-party sites, or reproduction of third-party content, do not constitute an approval or endorsement by Propel(x) or Hubble Investments, Propel(x)’ broker-dealer affiliate, of the linked or reproduced content.
Private Placements are a high-risk investment. An investment in such offerings is speculative and an investor could experience an entire loss of principal. Past performance may not be indicative of future results. Private investments are highly illiquid and risky and are not suitable for all investors. Investments in early-stage private companies should only be part of your overall investment portfolio.
Information provided in this article is not intended to be nor should it be construed or used as, investment, tax or legal advice, a recommendation, or an offer to sell, or a solicitation of an offer to buy, an interest, directly or indirectly, in the Company.